School of Public Health, University of Queensland, Brisbane, Queensland, Australia.
School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia.
Aust N Z J Obstet Gynaecol. 2023 Feb;63(1):27-33. doi: 10.1111/ajo.13548. Epub 2022 Jun 13.
Antenatal inactivated influenza (IIV) and pertussis-containing vaccines (dTpa) offer protection against severe respiratory infections for pregnant women and infants <6 months of age. Both vaccines are recommended in pregnancy; however, little is known about temporal or jurisdictional trends and predictors of uptake.
To identify gaps and predictors of IIV and/or dTpa vaccinations in Australian pregnancies from 2012 to 2017.
We conducted a probabilistically linked, multi-jurisdictional population-based cohort study, drawing from perinatal data collections and immunisation databases. We used a generalised linear mixed model with a random effect term to account for clustering of multiple pregnancies within mothers, to calculate vaccination uptake, and identify predictors of uptake by maternal demographic, pregnancy, and health characteristics.
Of 591 868 unique pregnancies, IIV uptake was 15%, dTpa 27% and 12% received both vaccines. Pertussis vaccinations in First Nations pregnancies were 20% lower than non-Indigenous pregnancies; dTpa was strongly associated with IIV uptake (risk ratio (RR): 8.60, 95% CI 8.48-8.73). This trend was temporally and jurisdictionally consistent. First Nations women were more likely to have had IIV in pregnancy before the introduction of dTpa in the pregnancy program: (RR: 1.48, 95% CI 1.40-1.57), but less likely after dTpa implementation (RR: 0.78, 95% CI 0.76-0.80).
Inequity in vaccine uptake between First Nations and non-Indigenous pregnancies, and dismal rates of vaccination in pregnancy overall need urgent review, particularly before the next influenza pandemic or pertussis outbreak. If antenatal dTpa is driving IIV uptake, changes in antenatal healthcare practices are needed to ensure vaccines are offered equitably and optimally to protect against infection.
产前灭活流感(IIV)和含百日咳疫苗(dTpa)为孕妇和 <6 个月龄婴儿提供针对严重呼吸道感染的保护。这两种疫苗都建议在怀孕期间使用;然而,对于接种的时间趋势和影响因素知之甚少。
确定 2012 年至 2017 年澳大利亚妊娠期间 IIV 和/或 dTpa 疫苗接种的差距和影响因素。
我们进行了一项概率性链接的多司法管辖区基于人群的队列研究,该研究来自围产期数据收集和免疫数据库。我们使用具有随机效应项的广义线性混合模型来计算接种率,并确定母体人口统计学、妊娠和健康特征对接种率的影响因素。
在 591868 个独特的妊娠中,接种 IIV 的比例为 15%,接种 dTpa 的比例为 27%,12%的人同时接种了这两种疫苗。原住民妊娠中的百日咳疫苗接种率比非原住民妊娠低 20%;dTpa 与 IIV 接种率呈强相关(风险比(RR):8.60,95%置信区间 8.48-8.73)。这种趋势在时间和司法管辖区内是一致的。在 dTpa 被纳入妊娠计划之前,原住民妇女在妊娠期间更有可能接种 IIV(RR:1.48,95%置信区间 1.40-1.57),但在 dTpa 实施后则不太可能(RR:0.78,95%置信区间 0.76-0.80)。
原住民和非原住民妊娠之间的疫苗接种率存在不平等,总体而言妊娠期间的疫苗接种率令人沮丧,需要紧急审查,特别是在下一次流感大流行或百日咳爆发之前。如果产前 dTpa 推动了 IIV 接种率的提高,那么需要改变产前保健实践,以确保公平、最佳地提供疫苗,以预防感染。